456 related articles for article (PubMed ID: 21215703)
1. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.
Chang CJ; Yang JY; Xia W; Chen CT; Xie X; Chao CH; Woodward WA; Hsu JM; Hortobagyi GN; Hung MC
Cancer Cell; 2011 Jan; 19(1):86-100. PubMed ID: 21215703
[TBL] [Abstract][Full Text] [Related]
2. Slug/β-catenin-dependent proinflammatory phenotype in hypoxic breast cancer stem cells.
Storci G; Bertoni S; De Carolis S; Papi A; Nati M; Ceccarelli C; Pirazzini C; Garagnani P; Ferrarini A; Buson G; Delledonne M; Fiorentino M; Capizzi E; Gruppioni E; Taffurelli M; Santini D; Franceschi C; Bandini G; Bonifazi F; Bonafé M
Am J Pathol; 2013 Nov; 183(5):1688-1697. PubMed ID: 24036252
[TBL] [Abstract][Full Text] [Related]
3. EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells.
Stefansson OA; Esteller M
Breast Cancer Res; 2011 May; 13(3):309. PubMed ID: 21672285
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells.
Li Y; Zhang T; Korkaya H; Liu S; Lee HF; Newman B; Yu Y; Clouthier SG; Schwartz SJ; Wicha MS; Sun D
Clin Cancer Res; 2010 May; 16(9):2580-90. PubMed ID: 20388854
[TBL] [Abstract][Full Text] [Related]
5. YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK.
Chang LC; Lin HY; Tsai MT; Chou RH; Lee FY; Teng CM; Hsieh MT; Hung HY; Huang LJ; Yu YL; Kuo SC
Br J Pharmacol; 2014 Sep; 171(17):4010-25. PubMed ID: 24697523
[TBL] [Abstract][Full Text] [Related]
6. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.
Shi B; Liang J; Yang X; Wang Y; Zhao Y; Wu H; Sun L; Zhang Y; Chen Y; Li R; Zhang Y; Hong M; Shang Y
Mol Cell Biol; 2007 Jul; 27(14):5105-19. PubMed ID: 17502350
[TBL] [Abstract][Full Text] [Related]
7. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
8. EZH2 is essential for glioblastoma cancer stem cell maintenance.
Suvà ML; Riggi N; Janiszewska M; Radovanovic I; Provero P; Stehle JC; Baumer K; Le Bitoux MA; Marino D; Cironi L; Marquez VE; Clément V; Stamenkovic I
Cancer Res; 2009 Dec; 69(24):9211-8. PubMed ID: 19934320
[TBL] [Abstract][Full Text] [Related]
9. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes.
Fujii S; Tokita K; Wada N; Ito K; Yamauchi C; Ito Y; Ochiai A
Oncogene; 2011 Sep; 30(39):4118-28. PubMed ID: 21499305
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.
Rizzo S; Hersey JM; Mellor P; Dai W; Santos-Silva A; Liber D; Luk L; Titley I; Carden CP; Box G; Hudson DL; Kaye SB; Brown R
Mol Cancer Ther; 2011 Feb; 10(2):325-35. PubMed ID: 21216927
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
12. EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling.
Chen JF; Luo X; Xiang LS; Li HT; Zha L; Li N; He JM; Xie GF; Xie X; Liang HJ
Oncotarget; 2016 Jul; 7(27):41540-41558. PubMed ID: 27172794
[TBL] [Abstract][Full Text] [Related]
13. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.
Yadav A; Kumar B; Teknos TN; Kumar P
Mol Cancer Ther; 2011 Jul; 10(7):1241-51. PubMed ID: 21551262
[TBL] [Abstract][Full Text] [Related]
16. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
[TBL] [Abstract][Full Text] [Related]
17. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
[TBL] [Abstract][Full Text] [Related]
19. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
20. The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells.
Zeidler M; Varambally S; Cao Q; Chinnaiyan AM; Ferguson DO; Merajver SD; Kleer CG
Neoplasia; 2005 Nov; 7(11):1011-9. PubMed ID: 16331887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
